KBL Merger Corp Acquires Cannabis-Focused Biotech Company

KBL Merger Corp. IV KBLM on Friday announced its acquisition of a new cannabis biotech company CannBioRx Life Sciences Corp.

CannBioRx Life Sciences Corp. has three synergistic programs that operate at the intersection of biotech and cannabis, and focuses on developing novel anti-inflammatory drugs for diseases like Crohn's and multiple sclerosis.

Pre-IPO Offer: Get A Piece Of A Nearly $5T Global Opportunity By Joining BOXABL As An Early Shareholder At Just $0.80/Share

• Massive Demand & Disruptive Potential – Boxabl has received interest for over 190,000 homes, positioning itself as a major disruptor in the housing market.
• Revolutionary Manufacturing Approach – Inspired by Henry Ford’s assembly line, Boxabl’s foldable tiny homes are designed for high-efficiency production, making homeownership more accessible.
• Affordable Investment Opportunity – With homes priced at $60,000, Boxabl is raising $1 billion to scale production, offering investors a chance to own a stake in its growth.

Share Price: $0.80

Min. Investment: $1,000

Valuation: $3.5B

Click Here To Invest For Just $0.80/Share ($1000 Min)

Benzinga's Cannabis Capital Conference heads to Detroit on Aug. 15 -- Click here to learn more!

The company was founded by Sir Marc Feldmann of Oxford and Lawrence Steinman of Stanford, who have significant expertise in developing successful therapeutics that resulted in billion-dollar markets, including blockbusters like Johnson & Johnson JNJ’s Remicade.

"We expect to be one of a limited number of NASDAQ-listed companies developing non-plant-touching, pharmaceutical-grade, non-psychoactive cannabinoids. These drugs are intended to provide safer, uniform dosing, according to regulatory agency standards," said Dr. Marlene Krauss, CEO of KBLM, who will also assume the role of CEO of CannBioRx Life Sciences Corp.